Filing Flows › Kyntra Bio (KYNB) › R&D spending
Kyntra Bio (KYNB) R&D spending by quarter
Kyntra Bio's R&D spending was $7.6M in Q1 2026 (first quarter 2026), +4% from Q4 2025. Over the last 5 quarters it ranged from $1.2M (Q3 2025) to $9.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $7.6M | +4% | -18% |
| Q4 2025 | $7.3M | +501% | — |
| Q3 2025 | $1.2M | -79% | — |
| Q2 2025 | $5.9M | -36% | — |
| Q1 2025 | $9.2M | — | — |
Q1 2026 at a glance
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kyntra Bio's R&D spending?
Kyntra Bio's R&D spending was $7.6M in Q1 2026 (first quarter 2026), +4% from Q4 2025.
How has Kyntra Bio's R&D spending changed?
Over the last 5 quarters it ranged from $1.2M (Q3 2025) to $9.2M (Q1 2025).